Multiple Sclerosis Clinical Trials in Washington, DC

30 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO	Phase 1	National Cancer Institute (NCI)	<1 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	Phase 3	Novartis Pharmaceuticals	<1 mi
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis	Phase 1	Amylyx Pharmaceuticals Inc.	<1 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis	Phase 3	Novartis Pharmaceuticals	<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	—	TG Therapeutics, Inc.	<1 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab	Phase 3	TG Therapeutics, Inc.	<1 mi
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis	Phase 1	AstraZeneca	<1 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	6 mi
Study of Skin Tumors in Tuberous Sclerosis	—	National Heart, Lung, and Blood Institute (NHLBI)	6 mi
Study of the Disease Process of Lymphangioleiomyomatosis	—	National Heart, Lung, and Blood Institute (NHLBI)	6 mi
Role of Genetic Factors in the Development of Lung Disease	—	National Heart, Lung, and Blood Institute (NHLBI)	6 mi
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques	Phase 2	National Institute of Neurological Disorders and Stroke (NINDS)	6 mi
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)	—	National Institute of Neurological Disorders and Stroke (NINDS)	6 mi
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring	—	Bristol-Myers Squibb	6 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy	Phase 1/2	UniQure Biopharma B.V.	6 mi
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)	Phase 1/2	National Institute of Allergy and Infectious Diseases (NIAID)	6 mi
Pathological Basis of MRI Signal Changes in Multiple Sclerosis	—	National Institute of Neurological Disorders and Stroke (NINDS)	6 mi
Genes and Environment in Multiple Sclerosis	—	Columbia University	6 mi
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy	Phase 1	National Institute of Neurological Disorders and Stroke (NINDS)	6 mi
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System	—	National Institute of Allergy and Infectious Diseases (NIAID)	6 mi
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)	—	National Institute of Neurological Disorders and Stroke (NINDS)	6 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	14 mi
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue	Phase 2	Johns Hopkins University	35 mi
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis	Phase 1	PRG Science & Technology Co., Ltd.	35 mi
Study of COYA 302 for the Treatment of ALS	Phase 2/3	Coya Therapeutics	35 mi
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis	Phase 3	Sanofi	35 mi
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study	N/A	SetPoint Medical Corporation	35 mi
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis	Phase 2	Johns Hopkins University	35 mi
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis	Phase 4	Johns Hopkins University	35 mi
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis	N/A	University of Maryland, Baltimore	35 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.